Market Overview

Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy

Share:
Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy
Related GILD
Why Gilead, Galapagos Shares Are Trading Higher
Fast Money Picks For September 12
Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative (Seeking Alpha)

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse.

The Analyst

Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target lowered from $82 to $80.

The Thesis

The case against being overweight Gilead's stock is simple: consensus estimates for the company's hepatitis C virus therapies are calling for sales of $5.1 billion in 2018, but a more reasonable estimate is $3.2 billion, Young said in a note. In prior years when consensus estimates were too high, shares of Gilead lost roughly 10 percent, and this pattern is likely to repeat in 2018, the analyst said. 

The Street's revenue estimate for the upcoming HIV bictegravir launch stands at $884 million versus Credit Suisse's $1.1-billion estimate, the analyst said. 

Credit Suisse's estimate for Yescarta revenue is $184 million, well short of the $230-million Street estimate.

After 2018, Gilead can accelerate its EPS growth by a 12-percent compound annual growth rate through 2023, Young said.  

"While we believe investors are aware that Street expectations remain too high for HCV ... we expect that consensus will need to be revised again after Gilead sets guidance, likely on its [fourth quarter of 2017] call in February." 

Price Action

Shares of Gilead were down slightly at $74.25 midday Wednesday and are higher by 3.6 percent since the start of 2017.

Related Links:

ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Maxim Explains Why Gilead Sciences Is A Now A Buy

Latest Ratings for GILD

DateFirmActionFromTo
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jul 2018BairdDowngradesOutperformNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Alethia YoungAnalyst Color Biotech Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (GILD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NKEOppenheimerUpgrades0.0
SBEvercore ISI GroupUpgrades4.5
PTIRBC CapitalUpgrades0.0
GPSJP MorganDowngrades24.0
GIIIB. Riley FBRUpgrades47.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

36 Stocks Moving In Wednesday's Mid-Day Session

Bitcoin Futures: What They Are And How To Trade Them